TVB 2640

Drug Profile

TVB 2640

Alternative Names: TVB-2640

Latest Information Update: 25 Feb 2017

Price : $50

At a glance

  • Originator 3-V Biosciences
  • Developer 3-V Biosciences; University of Kentucky
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Metabolic syndrome
  • Phase I Colorectal cancer; Solid tumours
  • Phase Unknown Astrocytoma

Most Recent Events

  • 09 Jun 2017 Mayo Clinic plans a phase II trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (NCT03179904)
  • 01 Feb 2017 Phase-I/II clinical trials in Metabolic syndrome in USA (PO) (NCT02948569)
  • 24 Jan 2017 Investigation in Astrocytoma in USA (PO) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top